Operating Expenses
Stock-Based Comp
Neurocrine Biosciences Stock-Based Comp decreased by 2.4% to $57.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.3%, from $52.80M to $57.20M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 12.9% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
Metric ID:
tjx_share_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $28.60M | $37.10M | $35.60M | $37.00M | $49.50M | $43.10M | $43.50M | $39.90M | $68.50M | $47.80M | $38.10M | $44.50M | $43.10M | $41.50M | $66.40M | $52.80M | $52.80M | $53.70M | $58.60M | $57.20M |
| QoQ Change | — | +29.7% | -4.0% | +3.9% | +33.8% | -12.9% | +0.9% | -8.3% | +71.7% | -30.2% | -20.3% | +16.8% | -3.1% | -3.7% | +60.0% | -20.5% | +0.0% | +1.7% | +9.1% | -2.4% |
| YoY Change | — | — | — | — | +73.1% | +16.2% | +22.2% | +7.8% | +38.4% | +10.9% | -12.4% | +11.5% | -37.1% | -13.2% | +74.3% | +18.7% | +22.5% | +29.4% | -11.7% | +8.3% |
Range$28.60M – $68.50M
CAGR+15.7%
Avg YoY Growth+16.2%
Median YoY Growth+13.9%
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's stock-based comp?
- Neurocrine Biosciences (NBIX) reported stock-based comp of $57.20M in Q1 2026.
- How has Neurocrine Biosciences's stock-based comp changed year-over-year?
- Neurocrine Biosciences's stock-based comp increased by 8.3% year-over-year, from $52.80M to $57.20M.
- What is the long-term trend for Neurocrine Biosciences's stock-based comp?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's stock-based comp has grown at a 12.9% compound annual growth rate (CAGR), from $134.20M to $217.90M.